Physician profile
Patrick Robert Dennison
NPI 1235370461
$5,842.00
in general payments reported to CMS, 2019-2025
38 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $125 · 2021: $436 · 2022: $1,307 · 2023: $1,772 · 2024: $2,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,833.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,224.57 | 2020-2024 | Ubrelvy, Qulipta, Mavyret |
| Astrazeneca Pharmaceuticals Lp | $1,002.26 | 2022-2024 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $898.14 | 2022-2024 | |
| Novo Nordisk INC | $424.36 | 2020-2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $207.42 | 2022-2023 | Verquvo, Belsomra |
| Gilead Sciences, INC. | $170.45 | 2021 | |
| Lundbeck LLC | $165.42 | 2024 | Rexulti |
| Pfizer INC. | $144.96 | 2021-2024 | |
| Edwards Lifesciences Corporation | $136.50 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Phathom Pharmaceuticals, INC. | $129.99 | 2024 | Voquezna |
| Abbott Laboratories | $126.15 | 2022-2024 | Freestyle Libre 3 |
| Orexo US, INC. | $120.22 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $99.10 | 2022-2024 | Eliquis |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.39 | 2022-2024 | Caplyta |
| Lilly USA, LLC | $82.11 | 2023-2024 | Mounjaro, Jardiance, Trulicity |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Dennison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.